Exelixis Inc Increase (Decrease) in Deferred Income Taxes
Exelixis Inc (EXEL) reported Increase (Decrease) in Deferred Income Taxes of -$126.24 million for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2026-02-10
- Exelixis Inc increase (decrease) in deferred income taxes for the quarter ending 2023-03-31 was $0.00.
- Exelixis Inc increase (decrease) in deferred income taxes for the quarter ending 2022-12-30 was $60.36M.
- Exelixis Inc increase (decrease) in deferred income taxes for the quarter ending 2022-09-30 was $0.00.
- Exelixis Inc increase (decrease) in deferred income taxes for the quarter ending 2022-07-01 was $15.32M.
- Exelixis Inc increase (decrease) in deferred income taxes for fiscal 2026 was -$126.24M, a 312.31% decline from fiscal 2025.
- Exelixis Inc increase (decrease) in deferred income taxes for fiscal 2025 was $59.46M, a 55.36% decline from fiscal 2023.
- Exelixis Inc increase (decrease) in deferred income taxes for fiscal 2023 was $133.21M, a 120.70% increase from fiscal 2022.
- Exelixis Inc increase (decrease) in deferred income taxes for fiscal 2022 was $60.36M.
| Period end | Increase (Decrease) in Deferred Income Taxes 3 month | Increase (Decrease) in Deferred Income Taxes 6 month | Increase (Decrease) in Deferred Income Taxes 9 month | Increase (Decrease) in Deferred Income Taxes 12 month |
|---|---|---|---|---|
| 2026-01-02 | -$126.24M 10-K · filed 2026-02-10 | |||
| 2025-01-03 | $59.46M 10-K · filed 2026-02-10 | |||
| 2023-12-29 | $133.21M 10-K · filed 2026-02-10 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $60.36M derived: sum of 2 quarters · filed 2025-02-11 | $60.36M derived: sum of 3 quarters · filed 2025-02-11 | $75.68M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-30 | $60.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $60.36M derived: sum of 2 quarters · filed 2025-02-11 | $75.68M derived: sum of 3 quarters · filed 2025-02-11 | $60.36M 10-K · filed 2025-02-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $15.32M derived: sum of 2 quarters · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | -$14.16M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | $15.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | -$14.16M derived: sum of 3 quarters · filed 2024-02-06 | -$23.73M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | -$15.32M 10-Q · filed 2023-05-09 | -$29.48M derived: sum of 2 quarters · filed 2024-02-06 | -$39.05M derived: sum of 3 quarters · filed 2024-02-06 | -$65.23M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | -$14.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | -$23.73M derived: sum of 2 quarters · filed 2024-02-06 | -$49.92M derived: sum of 3 quarters · filed 2024-02-06 | -$46.53M 10-K · filed 2024-02-06 |
| 2021-10-01 | -$9.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$35.75M derived: sum of 2 quarters · filed 2022-11-01 | -$32.37M 10-Q · filed 2022-11-01 | -$31.83M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | -$26.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$22.80M 10-Q · filed 2022-08-09 | -$22.26M derived: sum of 3 quarters · filed 2023-02-07 | -$15.27M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $3.39M 10-Q · filed 2022-05-10 | $3.93M derived: sum of 2 quarters · filed 2023-02-07 | $10.92M derived: sum of 3 quarters · filed 2023-02-07 | -$1.75M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | $538.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $7.53M derived: sum of 2 quarters · filed 2023-02-07 | -$5.14M derived: sum of 3 quarters · filed 2023-02-07 | -$15.27M 10-K · filed 2023-02-07 |
| 2020-10-02 | $6.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$5.67M derived: sum of 2 quarters · filed 2021-11-02 | -$15.80M 10-Q · filed 2021-11-02 | -$30.47M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | -$12.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$22.79M 10-Q · filed 2021-08-05 | -$37.46M derived: sum of 3 quarters · filed 2022-02-18 | -$60.73M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | -$10.13M 10-Q · filed 2021-05-06 | -$24.79M derived: sum of 2 quarters · filed 2022-02-18 | -$48.06M derived: sum of 3 quarters · filed 2022-02-18 | |
| 2020-01-03 | -$14.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$37.94M derived: sum of 2 quarters · filed 2022-02-18 | -$71.00M 10-K · filed 2022-02-18 | |
| 2019-09-27 | -$23.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$56.34M 10-Q · filed 2019-10-30 | ||
| 2019-06-28 | -$33.07M 10-Q · filed 2019-07-31 | |||
| 2018-12-28 | $244.11M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $244.11M derived: sum of 2 quarters · filed 2020-02-25 | $244.11M 10-K · filed 2021-02-11 | |
| 2018-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | ||
| 2018-06-29 | $0.00 10-Q · filed 2019-07-31 | |||
| 2017-12-29 | $0.00 10-K · filed 2020-02-25 | |||
| 2016-12-30 | $0.00 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |